Metohexal (Metoprolol Tartrate Ph. Eur.)

Metoprolol Tartrate selectively blocks β1‑adrenergic receptors in the heart, diminishing the effects of adrenaline. This leads to a slower heart rate, reduced contractility, and lower cardiac output, which together lower blood pressure and decrease the heart’s oxygen demand.

The appropriate dose of Metohexal is determined by a qualified prescriber based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the dosing instructions provided by their healthcare professional and not adjust the dose on their own.

Metohexal is classified as pregnancy category C, meaning risk cannot be ruled out. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician, as the drug may be excreted in breast milk.

To order Metohexal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Metohexal (metoprolol tartrate) is a cardio‑selective β1‑blocker, offering a favorable profile for patients with respiratory concerns compared with non‑selective agents. Its once‑ or twice‑daily dosing and proven efficacy in heart failure and post‑MI settings make it a common choice, though individual response and tolerability guide final selection.

Metohexal tablets should be stored at room temperature below 25 °C, in the original container, protected from moisture and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Metohexal is taken orally, usually with a glass of water. It may be taken with or without food, but patients should follow the prescribing physician’s guidance on timing relative to meals to maintain consistent absorption.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in susceptible individuals, and acute decompensated heart failure. Patients should seek immediate medical attention if they experience fainting, extreme fatigue, difficulty breathing, or rapid weight gain.

Metohexal is contraindicated in patients with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, cardiogenic shock, overt heart failure, and uncontrolled asthma or severe chronic obstructive pulmonary disease. It should also be avoided in individuals with known hypersensitivity to metoprolol or any excipients.